These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 31980145)

  • 1. [Does the FLOT regimen a new standard of perioperative chemotherapy for localized gastric cancer?].
    Adenis A; Samalin E; Mazard T; Portales F; Mourregot A; Ychou M
    Bull Cancer; 2020 Jan; 107(1):54-60. PubMed ID: 31980145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
    Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
    Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
    Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
    Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study.
    Moussa O; Bhogal RH; Malietzis G; Fribbens C; Starling N; Gerlinger M; Watkins D; Chau I; Rao S; Cunningham D; Allum WH; Chaudry A; Kumar S
    BJS Open; 2022 Jan; 6(1):. PubMed ID: 35195263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of perioperative FLOT compared to ECX/EOX chemotherapy regimens in resectable esophagogastric adenocarcinomas: an analysis of real-world data.
    Egebjerg K; Andersen TS; Bæksgaard L; Garbyal R; Siemsen M; Achiam M; Mau-Sørensen PM
    Acta Oncol; 2024 May; 63():322-329. PubMed ID: 38745482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma.
    Zeng H; Wang C; Song LY; Jia SJ; Zeng X; Liu Q
    BMJ Open; 2022 Nov; 12(11):e060983. PubMed ID: 36375981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer.
    Ocvirk J; Reberšek M; Skof E; Hlebanja Z; Boc M
    Am J Clin Oncol; 2012 Jun; 35(3):237-41. PubMed ID: 21399488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perioperative chemotherapy with 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) for esophagogastric adenocarcinoma: ten years real-life experience from a surgical perspective.
    Sisic L; Crnovrsanin N; Nienhueser H; Jung JO; Schiefer S; Haag GM; Bruckner T; Schneider M; Müller-Stich BP; Büchler MW; Schmidt T
    Langenbecks Arch Surg; 2023 Feb; 408(1):81. PubMed ID: 36763220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer.
    Lorenzen S; Pauligk C; Homann N; Schmalenberg H; Jäger E; Al-Batran SE
    Br J Cancer; 2013 Feb; 108(3):519-26. PubMed ID: 23322206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group.
    Hofheinz RD; Hegewisch-Becker S; Kunzmann V; Thuss-Patience P; Fuchs M; Homann N; Graeven U; Schulte N; Merx K; Pohl M; Held S; Keller R; Tannapfel A; Al-Batran SE
    Int J Cancer; 2021 Sep; 149(6):1322-1331. PubMed ID: 34019698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma - the phase III "PREVENT"- (FLOT9) trial of the AIO /CAOGI /ACO.
    Götze TO; Piso P; Lorenzen S; Bankstahl US; Pauligk C; Elshafei M; Amato G; Reim D; Bechstein WO; Königsrainer A; Mönig SP; Rau B; Schwarzbach M; Al-Batran SE
    BMC Cancer; 2021 Oct; 21(1):1158. PubMed ID: 34715810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma - A comparison of the FLOT and 'MAGIC' regimens.
    Moore JL; Kumar S; Santaolalla A; Patel PH; Kapiris M; Van Hemelrijck M; Maisey N; Hill M; Lagergren J; Gossage JA; Kelly M; Chaudry A; Allum WH; Baker CR; Cunningham D; Davies AR;
    Eur J Cancer; 2022 Mar; 163():180-188. PubMed ID: 35085931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-finding study of modified FLOT (mFLOT) regimen as first-line treatment in Chinese patients with metastatic adenocarcinoma of stomach.
    Zhou C; Ma T; Shi M; Xi W; Wu J; Yang C; Zhu Z; Zhang J
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):113-119. PubMed ID: 31691079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of the observational prospective RealFLOT study.
    Giommoni E; Lavacchi D; Tirino G; Fornaro L; Iachetta F; Pozzo C; Satolli MA; Spallanzani A; Puzzoni M; Stragliotto S; Sisani M; Formica V; Giovanardi F; Strippoli A; Prisciandaro M; Di Donato S; Pompella L; Pecora I; Romagnani A; Fancelli S; Brugia M; Pillozzi S; De Vita F; Antonuzzo L
    BMC Cancer; 2021 Oct; 21(1):1086. PubMed ID: 34625033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
    Glatz T; Bronsert P; Schäfer M; Kulemann B; Marjanovic G; Sick O; Hopt UT; Zirlik K; Makowiec F; Hoeppner J
    Eur J Surg Oncol; 2015 Oct; 41(10):1300-7. PubMed ID: 26253194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
    Dos Santos M; Lequesne J; Leconte A; Corbinais S; Parzy A; Guilloit JM; Varatharajah S; Brachet PE; Dorbeau M; Vaur D; Weiswald LB; Poulain L; Le Gallic C; Castera-Tellier M; Galais MP; Clarisse B
    BMC Cancer; 2022 May; 22(1):537. PubMed ID: 35549674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study.
    Guimbaud R; Louvet C; Ries P; Ychou M; Maillard E; André T; Gornet JM; Aparicio T; Nguyen S; Azzedine A; Etienne PL; Boucher E; Rebischung C; Hammel P; Rougier P; Bedenne L; Bouché O
    J Clin Oncol; 2014 Nov; 32(31):3520-6. PubMed ID: 25287828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of neoadjuvant FLOT treatment of advanced gastric and gastroesophageal junction cancer following surgical therapy.
    Paszt A; Simonka Z; Budai K; Horvath Z; Erdos M; Vas M; Ottlakan A; Nyari T; Szepes Z; Uhercsak G; Maraz A; Torday L; Tiszlavicz L; Olah J; Lazar G
    Front Surg; 2023; 10():1148984. PubMed ID: 37077865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer.
    Petrioli R; Marrelli D; Roviello F; D'Ignazio A; Torre P; Chirra M; Savelli V; Ambrosio MR; Francini G; Calomino N; Farsi M; Vernillo R; Francini E
    Surg Oncol; 2020 Mar; 32():2-7. PubMed ID: 31670056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial.
    Ochenduszko S; Puskulluoglu M; Konopka K; Fijorek K; Urbanczyk K; Budzynski A; Matlok M; Lazar A; Sinczak-Kuta A; Pedziwiatr M; Krzemieniecki K
    Med Oncol; 2015 Oct; 32(10):242. PubMed ID: 26354521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.